OR WAIT null SECS
German manufacturer metabion is conducting a multi-million euro expansion of its oligonucleotide manufacturing capacity in Munich East.
metabion, a German manufacturer of custom oligonucleotides, announced on July 11, 2023 that it has increased its global production capacity for both diagnostic and new therapeutic oligonucleotides, as well as derivatives, at its new facility in Munich East, Germany. The company completed a double-digit million euro investment in the 2023 first quarter for the expansion project.
The company has planned, built, and established the new oligonucleotide manufacturing facility over the past two years. The facility is dedicated to the manufacturing of small-, mid-, and large-scale oligonucleotide components for in-vitro diagnostics/analyte-specific reagents oligonucleotides as well as mid-/large-scale oligonucleotides for R&D and therapeutic applications. The increased capacity is intended to support the rising demand in Europe and worldwide for diagnostic and therapeutic oligonucleotides, according to a company press release.
"With this investment, we are strengthening our CMO [custom manufacturing organization] segment and are committed to further expanding our growth area of business," said Regina Bichlmaier, CEO of metabion, in the company press release. "At the same time, we are responding to an increasing demand for highly customized diagnostic solutions including packaging/kitting/OEM [original equipment manufacturer] services and supporting early stage oligonucleotide-based drug development from lead discovery and optimization to pre-clinical development into clinical [P]hase I and II.”